Pyxis Oncology (PYXS) investor relations material

Executive summary

• Clinical-stage oncology company focused on solid tumors, especially head and neck squamous cell carcinoma (HNSCC), with lead candidate MICVO (PYX-201) in Phase 1/2 trials as monotherapy and in combination with pembrolizumab (KEYTRUDA®).

• Advanced MICVO clinical program with key data updates expected mid- and late-2026 for monotherapy and combination therapy in R/M HNSCC.

• Positive preliminary efficacy and safety data reported for MICVO in both monotherapy and combination settings, with new preclinical data supporting efficacy.

• Fast Track Designation granted by FDA for MICVO in R/M HNSCC; Orphan Drug Designation in pancreatic cancer.

• Leadership changes include appointment of Nelson Azoulay as Chief Business Officer, Thomas Civik as Interim CEO, and resignation of Lara Sullivan.

Financial highlights

• Net loss of $23.3 million ($0.37 per share) for Q1 2026, compared to $21.2 million ($0.35 per share) in Q1 2025.

• Research and development expenses increased to $20.0 million, mainly due to expanded MICVO clinical trials.

• General and administrative expenses decreased to $4.4 million from $5.9 million year-over-year, primarily from lower stock-based compensation.

• Cash, cash equivalents, and marketable securities totaled $42.5 million as of March 31, 2026.

• Accumulated deficit reached $466.4 million as of March 31, 2026.

Outlook and guidance

• Cash resources expected to fund operations into Q4 2026; substantial doubt exists about ability to continue as a going concern beyond that period.

• Additional capital will be required to continue operations and advance clinical programs.

• Updated clinical data from MICVO monotherapy and combination cohorts expected mid and late 2026.